Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmaceutical-Grade Rigosertib Is a Microtubule-Destabilizing Agent.

Molecular cell - 2 Jul 2020

Jost Marco, Chen Yuwen, Gilbert Luke A, Horlbeck Max A, Krenning Lenno, Menchon Grégory, Rai Ankit, Cho Min Y, Stern Jacob J, Prota Andrea E, Kampmann Martin, Akhmanova Anna, Steinmetz Michel O, Tanenbaum Marvin E, Weissman Jonathan S

Abstract excerpt

We recently used CRISPRi/a-based chemical-genetic screens and cell biological, biochemical, and structural assays to determine that rigosertib, an anti-cancer agent in phase III clinical trials, kills cancer cells by destabilizing microtubules. Reddy and co-workers (Baker et al., 2020, this issue of Molecular Cell) suggest that a contaminating degradation product in commercial formulations of rigosertib is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Crystallography, X-Ray

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Contamination

Share to Glycine

Share to Microtubules

Share to Pharmaceutical Preparations

Share to Sulfones

Share to Tubulin

Source

Open in PubMed Open full text

Identifiers

PMID: 32619469
DOI: 10.1016/j.molcel.2020.06.008
PMCID: PMC7332992

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmaceutical-Grade Rigosertib Is a Microtubule-Destabilizing Agent.PMID 32619469Read ↗

Pharmaceutical-grade Rigosertib is a Microtubule-destabilizing AgentSemantic proximity Read ↗

Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent.Semantic proximity Read ↗

Functional genetics reveals modulators of anti-microtubule drug sensitivitySemantic proximity Read ↗

A Contaminant Impurity, Not Rigosertib, Is a Tubulin Binding Agent.Semantic proximity Read ↗

Mechanism of action of rigosertib does not involve tubulin bindingSemantic proximity Read ↗

Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistanceSemantic proximity Read ↗

Microtubule-Targeting Drugs: More than AntimitoticsSemantic proximity Read ↗

Diverse microtubule-destabilizing drugs induce equivalent molecular pathway responses in endothelial cellsSemantic proximity Read ↗

Repositioning Microtubule Stabilizing Drugs for Brain DisordersSemantic proximity Read ↗

Targeting and extending the eukaryotic druggable genome with natural products: cytoskeletal targets of natural productsSemantic proximity Read ↗

Cevipabulin-tubulin complex reveals a novel agent binding site on α-tubulin with tubulin degradation effectSemantic proximity Read ↗

TK216 targets microtubules in Ewing sarcoma cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.